This study is looking for adults aged 55 to 82 who are experiencing early signs of memory or cognitive (thinking) decline. The purpose is to see if a special form of omega-3 fatty acids, called LPC-EPA+DHA (Lysoveta), can better deliver DHA to the brain compared to another form, TAG-DHA. Researchers will measure DHA levels in your cerebrospinal fluid (the fluid around your brain and spinal cord) and blood after 24 weeks of taking capsules. They also hope to see improvements in markers related to brain health. This is a placebo-controlled study, meaning some participants will receive an inactive substance, to help understand the true effects of the intervention. The study is currently unclear about its recruitment status and aims to enroll 153 participants.

Study design

This is an interventional, placebo-controlled study comparing LPC-EPA+DHA and TAG-DHA in 153 elderly adults.

What's involved

Participants will take capsules for 24 weeks. A lumbar puncture (spinal tap) to collect cerebrospinal fluid may be required, unless there's a medical reason not to have one.

Compensation

Not stated in the trial record.

Follow-up

DHA levels will be measured from baseline through week 24.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.